How Cosentyx Works on the Immune System
Cosentyx (secukinumab) is a monoclonal antibody that targets interleukin-17A (IL-17A), a cytokine driving inflammation in autoimmune conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis. By binding IL-17A, it blocks its interaction with receptors on immune cells, reducing pro-inflammatory signaling and downstream effects like T-cell activation and neutrophil recruitment.[1]
Mechanism in Older Adults
The core mechanism remains the same across age groups: selective IL-17A inhibition dampens Th17-mediated inflammation without broadly suppressing the immune system, unlike TNF inhibitors. In older adults (typically 65+), studies show similar efficacy and pharmacokinetics to younger patients, with no dose adjustments needed. However, age-related immune changes—such as immunosenescence (declining T-cell diversity and function)—may amplify vulnerability to infections due to baseline frailty.[2][3]
Infection Risks Specific to Seniors
Older adults on Cosentyx face heightened infection rates, particularly upper respiratory and urinary tract infections, mirroring broader biologic trends. Pooled trial data (including patients up to 85) report serious infections in 2-3% of users, rising with age and comorbidities like diabetes. IL-17's role in mucosal immunity means blocking it can impair defenses against candida and bacteria; seniors' reduced skin barrier and lymphopenia exacerbate this.[4][5] Real-world registries note 1.5-2x higher hospitalization risk for infections in those over 65 versus under 50.
Other Immune Effects and Monitoring
Cosentyx rarely causes broad immunosuppression but can trigger inflammatory bowel disease flares (0.1-1%) or hypersensitivity. In older adults, monitor for reactivation of latent infections (e.g., TB screening required pre-treatment). Vaccination responses may wane, so administer inactivated vaccines before starting.[3][6] No increased malignancy signal in seniors, though long-term data is limited.
Comparisons to Alternatives
| Drug | Target | Infection Risk in Seniors | Key Difference |
|------|--------|---------------------------|---------------|
| Cosentyx (IL-17) | IL-17A | Moderate (respiratory focus) | More skin-specific; lower GI risk than anti-TNF |
| Humira (adalimumab) | TNF-alpha | Higher overall | Broader suppression; more opportunistic infections |
| Stelara (ustekinumab) | IL-12/23 | Lower | Targets fewer pathways; better for Crohn's in elderly |
Anti-IL-17 agents like Cosentyx show marginally lower serious infection rates (OR 1.2-1.5) than anti-TNF in head-to-head data for older psoriasis patients.[7]
[1] FDA Label for Cosentyx
[2] Novartis Cosentyx Prescribing Information
[3] JAMA Dermatology: Secukinumab Safety in Elderly
[4] British Journal of Dermatology: Infections in Older Psoriasis Patients on Biologics
[5] Annals of Rheumatic Diseases: IL-17 Inhibition and Immunity
[6] CDC Guidelines: Vaccinations with Immunosuppressants
[7] Lancet Rheumatology: Biologic Comparisons in Geriatric Rheumatology